PUBLIC RELEASE DATE: <\/p>\n
24-Feb-2014 <\/p>\n
Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News<\/p>\n New Rochelle, NY, February 24, 2014The automatic \"threshold suspend\" (TS) feature of an insulin pump helps prevent life-threatening hypoglycemic events when the device's sensor detects blood glucose concentrations below the preset threshold. However, in individuals with type 1 diabetes who have had previous episodes of hypoglycemia the TS feature may be less effective at preventing subsequent events, according to important new results from the ASPIRE study published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http:\/\/www.liebertpub.com\/DTT<\/a>. <\/p>\n In the article \"Hypoglycemia Begets Hypoglycemia: The Order Effect in the ASPIRE In-Clinic Study,\" Editor-in-Chief of Diabetes Technology & Therapeutics Satish Garg, MD (Professor of Medicine and Pediatrics at the University of Colorado Denver) and coauthors compared the effects of an automatic insulin pump with TS at a preset sensor threshold to those of continued basal insulin delivery in adults with type 1 diabetes following induced hypoglycemia via overnight fasting and exercise. <\/p>\n The different outcomes seen between the two insulin delivery methods in this crossover study design led the authors to conclude that \"By mitigating the duration of hypoglycemic episodes, automatic pump suspension may help to preserve the normal autonomic response to hypoglycemia in patients with type 1 diabetes.\" <\/p>\n ### <\/p>\n About the Journal <\/p>\n Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http:\/\/www.liebertpub.com\/DTT<\/a>. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference. <\/p>\n About ATTD <\/p>\n <\/p>\n Here is the original post: PUBLIC RELEASE DATE: 24-Feb-2014 Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, February 24, 2014The automatic \"threshold suspend\" (TS) feature of an insulin pump helps prevent life-threatening hypoglycemic events when the device's sensor detects blood glucose concentrations below the preset threshold. However, in individuals with type 1 diabetes who have had previous episodes of hypoglycemia the TS feature may be less effective at preventing subsequent events, according to important new results from the ASPIRE study published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Continue reading
\nIs previous hypoglycemia a risk factor for future hypoglycemic episodes?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"